Tourmaline Bio (TRML) has released an update.
On October 19, 2023, the Delaware corporation previously known as Talaris Therapeutics, Inc. finalized its merger with Legacy Tourmaline, now known as Tourmaline Sub, Inc., making it a direct wholly owned subsidiary. Post-merger, the company adopted the name Tourmaline Bio, Inc. and shifted its primary business focus to the operations previously conducted by Legacy Tourmaline.
For further insights into TRML stock, check out TipRanks’ Stock Analysis page.
